Selected research
Industry Research
Sterile Formulation Development Industry Research Report 2026
Market perspective
The global Sterile Formulation Development market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Sterile Formulation Development market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Sterile Formulation Development market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Sterile Formulation Development market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Sterile Formulation Development include Catalent, Lonza Group AG, Recipharm AB, Samsung Biologics, Aenova Group, Thermo Fisher Scientific, Pfizer CentreOne, Piramal Pharma Solutions and Ardena, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Sterile Formulation Development market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Sterile Formulation Development.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Sterile Formulation Development Market by Company
Catalent
Lonza Group AG
Recipharm AB
Samsung Biologics
Aenova Group
Thermo Fisher Scientific
Pfizer CentreOne
Piramal Pharma Solutions
Ardena
Curida
Curia Global
Carbogen Amcis
Oakwood Labs
Cambrex
Almac Group
Asymchem Group
AGC Biologics
WuXi AppTec
Althea
Baxter
Sterile Formulation Development Segment by Type
Liquid Dosage Form
Lyophilized Dosage Form
Frozen Dosage Form
Others
Sterile Formulation Development Segment by Application
Preclinical
Clinical
Commercial
Sterile Formulation Development Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sterile Formulation Development market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sterile Formulation Development and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sterile Formulation Development.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Sterile Formulation Development companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Liquid Dosage Form
- Lyophilized Dosage Form
- Frozen Dosage Form
- Others
Applications
- Preclinical
- Clinical
- Commercial
Companies covered
- Catalent
- Lonza Group AG
- Recipharm AB
- Samsung Biologics
- Aenova Group
- Thermo Fisher Scientific
- Pfizer CentreOne
- Piramal Pharma Solutions
- Ardena
- Curida
- Curia Global
- Carbogen Amcis
- Oakwood Labs
- Cambrex
- Almac Group
- Asymchem Group
- AGC Biologics
- WuXi AppTec
- Althea
- Baxter
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Sterile Formulation Development by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Liquid Dosage Form
- 2.2.3 Lyophilized Dosage Form
- 2.2.4 Frozen Dosage Form
- 2.2.5 Others
- 2.3 Sterile Formulation Development by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Preclinical
- 2.3.3 Clinical
- 2.3.4 Commercial
- 2.4 Assumptions and Limitations
3 Sterile Formulation Development Breakdown Data by Type
- 3.1 Global Sterile Formulation Development Historic Market Size by Type (2021-2026)
- 3.2 Global Sterile Formulation Development Forecasted Market Size by Type (2027-2032)
4 Sterile Formulation Development Breakdown Data by Application
- 4.1 Global Sterile Formulation Development Historic Market Size by Application (2021-2026)
- 4.2 Global Sterile Formulation Development Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Sterile Formulation Development Market Perspective (2021-2032)
- 5.2 Global Sterile Formulation Development Growth Trends by Region
- 5.2.1 Global Sterile Formulation Development Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Sterile Formulation Development Historic Market Size by Region (2021-2026)
- 5.2.3 Sterile Formulation Development Forecasted Market Size by Region (2027-2032)
- 5.3 Sterile Formulation Development Market Dynamics
- 5.3.1 Sterile Formulation Development Industry Trends
- 5.3.2 Sterile Formulation Development Market Drivers
- 5.3.3 Sterile Formulation Development Market Challenges
- 5.3.4 Sterile Formulation Development Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Sterile Formulation Development Players by Revenue
- 6.1.1 Global Top Sterile Formulation Development Players by Revenue (2021-2026)
- 6.1.2 Global Sterile Formulation Development Revenue Market Share by Players (2021-2026)
- 6.2 Global Sterile Formulation Development Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Sterile Formulation Development Head Office and Area Served
- 6.4 Global Sterile Formulation Development Players, Product Type & Application
- 6.5 Global Sterile Formulation Development Manufacturers Established Date
- 6.6 Global Sterile Formulation Development Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Sterile Formulation Development Market Size (2021-2032)
- 7.2 North America Sterile Formulation Development Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Sterile Formulation Development Market Size by Country (2021-2026)
- 7.4 North America Sterile Formulation Development Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Sterile Formulation Development Market Size (2021-2032)
- 8.2 Europe Sterile Formulation Development Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Sterile Formulation Development Market Size by Country (2021-2026)
- 8.4 Europe Sterile Formulation Development Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Sterile Formulation Development Market Size (2021-2032)
- 9.2 Asia-Pacific Sterile Formulation Development Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Sterile Formulation Development Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Sterile Formulation Development Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Sterile Formulation Development Market Size (2021-2032)
- 10.2 South America Sterile Formulation Development Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Sterile Formulation Development Market Size by Country (2021-2026)
- 10.4 South America Sterile Formulation Development Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Sterile Formulation Development Market Size (2021-2032)
- 11.2 Middle East & Africa Sterile Formulation Development Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Sterile Formulation Development Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Sterile Formulation Development Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Catalent
- 12.1.1 Catalent Company Information
- 12.1.2 Catalent Business Overview
- 12.1.3 Catalent Revenue in Sterile Formulation Development Business (2021-2026)
- 12.1.4 Catalent Sterile Formulation Development Product Portfolio
- 12.1.5 Catalent Recent Developments
- 12.2 Lonza Group AG
- 12.2.1 Lonza Group AG Company Information
- 12.2.2 Lonza Group AG Business Overview
- 12.2.3 Lonza Group AG Revenue in Sterile Formulation Development Business (2021-2026)
- 12.2.4 Lonza Group AG Sterile Formulation Development Product Portfolio
- 12.2.5 Lonza Group AG Recent Developments
- 12.3 Recipharm AB
- 12.3.1 Recipharm AB Company Information
- 12.3.2 Recipharm AB Business Overview
- 12.3.3 Recipharm AB Revenue in Sterile Formulation Development Business (2021-2026)
- 12.3.4 Recipharm AB Sterile Formulation Development Product Portfolio
- 12.3.5 Recipharm AB Recent Developments
- 12.4 Samsung Biologics
- 12.4.1 Samsung Biologics Company Information
- 12.4.2 Samsung Biologics Business Overview
- 12.4.3 Samsung Biologics Revenue in Sterile Formulation Development Business (2021-2026)
- 12.4.4 Samsung Biologics Sterile Formulation Development Product Portfolio
- 12.4.5 Samsung Biologics Recent Developments
- 12.5 Aenova Group
- 12.5.1 Aenova Group Company Information
- 12.5.2 Aenova Group Business Overview
- 12.5.3 Aenova Group Revenue in Sterile Formulation Development Business (2021-2026)
- 12.5.4 Aenova Group Sterile Formulation Development Product Portfolio
- 12.5.5 Aenova Group Recent Developments
- 12.6 Thermo Fisher Scientific
- 12.6.1 Thermo Fisher Scientific Company Information
- 12.6.2 Thermo Fisher Scientific Business Overview
- 12.6.3 Thermo Fisher Scientific Revenue in Sterile Formulation Development Business (2021-2026)
- 12.6.4 Thermo Fisher Scientific Sterile Formulation Development Product Portfolio
- 12.6.5 Thermo Fisher Scientific Recent Developments
- 12.7 Pfizer CentreOne
- 12.7.1 Pfizer CentreOne Company Information
- 12.7.2 Pfizer CentreOne Business Overview
- 12.7.3 Pfizer CentreOne Revenue in Sterile Formulation Development Business (2021-2026)
- 12.7.4 Pfizer CentreOne Sterile Formulation Development Product Portfolio
- 12.7.5 Pfizer CentreOne Recent Developments
- 12.8 Piramal Pharma Solutions
- 12.8.1 Piramal Pharma Solutions Company Information
- 12.8.2 Piramal Pharma Solutions Business Overview
- 12.8.3 Piramal Pharma Solutions Revenue in Sterile Formulation Development Business (2021-2026)
- 12.8.4 Piramal Pharma Solutions Sterile Formulation Development Product Portfolio
- 12.8.5 Piramal Pharma Solutions Recent Developments
- 12.9 Ardena
- 12.9.1 Ardena Company Information
- 12.9.2 Ardena Business Overview
- 12.9.3 Ardena Revenue in Sterile Formulation Development Business (2021-2026)
- 12.9.4 Ardena Sterile Formulation Development Product Portfolio
- 12.9.5 Ardena Recent Developments
- 12.10 Curida
- 12.10.1 Curida Company Information
- 12.10.2 Curida Business Overview
- 12.10.3 Curida Revenue in Sterile Formulation Development Business (2021-2026)
- 12.10.4 Curida Sterile Formulation Development Product Portfolio
- 12.10.5 Curida Recent Developments
- 12.11 Curia Global
- 12.11.1 Curia Global Company Information
- 12.11.2 Curia Global Business Overview
- 12.11.3 Curia Global Revenue in Sterile Formulation Development Business (2021-2026)
- 12.11.4 Curia Global Sterile Formulation Development Product Portfolio
- 12.11.5 Curia Global Recent Developments
- 12.12 Carbogen Amcis
- 12.12.1 Carbogen Amcis Company Information
- 12.12.2 Carbogen Amcis Business Overview
- 12.12.3 Carbogen Amcis Revenue in Sterile Formulation Development Business (2021-2026)
- 12.12.4 Carbogen Amcis Sterile Formulation Development Product Portfolio
- 12.12.5 Carbogen Amcis Recent Developments
- 12.13 Oakwood Labs
- 12.13.1 Oakwood Labs Company Information
- 12.13.2 Oakwood Labs Business Overview
- 12.13.3 Oakwood Labs Revenue in Sterile Formulation Development Business (2021-2026)
- 12.13.4 Oakwood Labs Sterile Formulation Development Product Portfolio
- 12.13.5 Oakwood Labs Recent Developments
- 12.14 Cambrex
- 12.14.1 Cambrex Company Information
- 12.14.2 Cambrex Business Overview
- 12.14.3 Cambrex Revenue in Sterile Formulation Development Business (2021-2026)
- 12.14.4 Cambrex Sterile Formulation Development Product Portfolio
- 12.14.5 Cambrex Recent Developments
- 12.15 Almac Group
- 12.15.1 Almac Group Company Information
- 12.15.2 Almac Group Business Overview
- 12.15.3 Almac Group Revenue in Sterile Formulation Development Business (2021-2026)
- 12.15.4 Almac Group Sterile Formulation Development Product Portfolio
- 12.15.5 Almac Group Recent Developments
- 12.16 Asymchem Group
- 12.16.1 Asymchem Group Company Information
- 12.16.2 Asymchem Group Business Overview
- 12.16.3 Asymchem Group Revenue in Sterile Formulation Development Business (2021-2026)
- 12.16.4 Asymchem Group Sterile Formulation Development Product Portfolio
- 12.16.5 Asymchem Group Recent Developments
- 12.17 AGC Biologics
- 12.17.1 AGC Biologics Company Information
- 12.17.2 AGC Biologics Business Overview
- 12.17.3 AGC Biologics Revenue in Sterile Formulation Development Business (2021-2026)
- 12.17.4 AGC Biologics Sterile Formulation Development Product Portfolio
- 12.17.5 AGC Biologics Recent Developments
- 12.18 WuXi AppTec
- 12.18.1 WuXi AppTec Company Information
- 12.18.2 WuXi AppTec Business Overview
- 12.18.3 WuXi AppTec Revenue in Sterile Formulation Development Business (2021-2026)
- 12.18.4 WuXi AppTec Sterile Formulation Development Product Portfolio
- 12.18.5 WuXi AppTec Recent Developments
- 12.19 Althea
- 12.19.1 Althea Company Information
- 12.19.2 Althea Business Overview
- 12.19.3 Althea Revenue in Sterile Formulation Development Business (2021-2026)
- 12.19.4 Althea Sterile Formulation Development Product Portfolio
- 12.19.5 Althea Recent Developments
- 12.20 Baxter
- 12.20.1 Baxter Company Information
- 12.20.2 Baxter Business Overview
- 12.20.3 Baxter Revenue in Sterile Formulation Development Business (2021-2026)
- 12.20.4 Baxter Sterile Formulation Development Product Portfolio
- 12.20.5 Baxter Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst